Comment on Aldén et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr. Issues Mol. Biol. 2022, 44, 1115–1126

Research output: Contribution to journalComment/debatepeer-review

Abstract

The intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 was recently demonstrated in vitro in a human liver cell line (Huh7) and raised significant concerns in the media over the consequential potential for genotoxicity among vaccinated subjects. The novel COVID-19 vaccines have been subject to controversies since the very beginning, and concerns over their potential to be incorporated into the human genome or to alter human DNA have been a major public concern, also exploited by anti-vaccine campaigners, and have significantly affected vaccine uptake and corroborated vaccine hesitancy globally. This article explains why such a phenomenon., demonstrated recently in vitro, may not manifest clinically in in vivo and therefore cannot be generalised to the healthy population.
Original languageEnglish
Pages (from-to)1661-1663
Number of pages3
JournalCurrent Issues in Molecular Biology
Volume44
Issue number4
DOIs
Publication statusPublished - 11 Apr 2022

Fingerprint

Dive into the research topics of 'Comment on Aldén et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr. Issues Mol. Biol. 2022, 44, 1115–1126'. Together they form a unique fingerprint.

Cite this